Quanterix Faces Revenue Challenges Amid Project Delays and Tariff Impacts, Holds Rating Due to Cautious Outlook

Analyst Puneet Souda of Leerink Partners maintained a Hold rating on Quanterix (QTRX – Research Report), retaining the price target of $8.00.

Puneet Souda has given his Hold rating due to a combination of factors impacting Quanterix’s financial outlook. The company reported stronger-than-expected revenue for the first quarter of 2025, but it significantly lowered its annual revenue guidance due to delays in large projects and a challenging outlook for the US academic sector. Additionally, the impact of tariffs further pressures revenue expectations.
Despite these challenges, Quanterix is implementing cost-cutting measures aimed at achieving cash flow profitability by 2026, including expected savings from synergies with AKYA. However, these cost reductions might limit the company’s ability to promote new products or compete effectively in the market. The resilience in product revenue, particularly in consumables, provides some optimism, but the overall cautious outlook justifies the Hold rating.

Souda covers the Healthcare sector, focusing on stocks such as Illumina, Repligen, and Guardant Health. According to TipRanks, Souda has an average return of -12.1% and a 29.84% success rate on recommended stocks.

In another report released on May 12, TD Cowen also maintained a Hold rating on the stock with a $7.00 price target.